---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-223242"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:37:38.623802+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# FDA approves Zevra's MIPLYFFA for NPC; XOMA holds royalty on sales up to $52.6M milestones

## Summary
- FDA approved MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) on Sept 20, 2024.
- XOMA is entitled to a mid-single digit royalty on commercial sales of MIPLYFFA.
- XOMA may receive up to $52.6 million (net) in milestone payments from Zevra.
- MIPLYFFA is the sixth commercial asset in XOMA's royalty and milestone portfolio.

## SEC filing metadata
- accession: 0001193125-24-223242
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312524223242/0001193125-24-223242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312524223242/d836129d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-223242
- JSON: https://secwatch.observer/filing/0001193125-24-223242.json
- Plain text: https://secwatch.observer/filing/0001193125-24-223242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.